Sequential Proteolytic Processing of the Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) Protein by Ectodomain Shedding and -Secretase-dependent Intramembranous Cleavage

Wunderlich, P

http://hdl.handle.net/10026.1/13247

10.1074/jbc.m113.517540
Journal of Biological Chemistry
Elsevier BV

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Sequential Proteolytic Processing of the Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) Protein by Ectodomain Shedding and γ-Secretase-dependent Intramembranous Cleavage*

Received for publication, September 10, 2013 Published, JBC Papers in Press, September 27, 2013, DOI 10.1074/jbc.M113.517540

Patrick Wunderlich1†, Konstantin Glebov1, Nadja Kemmerling1, Nguyen T. Tien1, Harald Neumann1, and Jochen Walter1‡1

From the 1Department of Neurology, University of Bonn, 53127 Bonn, Germany and the 2Institute of Reconstructive Neurobiology, University of Bonn, 53127 Bonn, Germany

Abstract

Triggering receptor expressed on myeloid cells-2 (TREM2) and its signaling adaptor protein TYROBP/DAP12 play important roles in signal transduction in dendritic cells, osteoclasts, tissue macrophages, and microglia. Recently, TREM2 variants have been shown to be linked to late onset Alzheimer disease. Here, we demonstrate that TREM2 undergoes sequential proteolytic processing by ectodomain shedding and intramembranous proteolysis. The C-terminal fragment (CTF) of TREM2 generated by ectodomain shedding is cleaved by γ-secretase and affects signaling via its adaptor protein DAP12. Thus, the accumulated TREM2 CTF thereby might limit the interaction of DAP12 with the functional full-length receptor, resulting in decreased DAP12 phosphorylation and impaired metabolism of phosphatidylinositol 4,5-bisphosphate. Together, these data demonstrate γ-secretase-mediated intramembranous proteolysis of TREM2 and functionally link two Alzheimer disease-associated proteins in one signaling pathway.

The triggering receptor expressed on myeloid cells-2 (TREM2)2 is a ~40-kDa type I membrane glycoprotein with a single extracellular immunoglobulin-like domain, one transmembrane domain, and a short cytoplasmatic tail. Although the cytoplasmic domain of TREM2 does not contain an overt amino acid-based signaling motif, its transmembrane domain interacts with the adaptor protein TYROBP/DNAX-activating protein of 12 kDa (DAP12) via electrostatic interaction (1, 2). TREM2 was originally identified on monocyte-derived dendritic cells (3), but was later also detected on several myeloid cell types including osteoclasts, tissue macrophages, and microglia (1). TREM2 is localized predominantly in the Golgi complex, but also shuttles to and from the cell surface in endocytic and exocytic vesicles (4, 5).

DAP12 is a type I transmembrane protein, which acts as a signaling adaptor protein for TREM2 and a number of other cell surface receptors (6). The cytoplasmic domain of DAP12 contains an immunoreceptor tyrosine activation motif (ITAM) (1, 7). After activation of the interacting receptor, DAP12 undergoes phosphorylation at the two conserved ITAM tyrosine residues by Src kinases. Subsequent recruitment and activation of the Syk protein kinase trigger downstream signaling pathways, including the activation of mitogen-activated protein kinase (MAPK) and phospholipase Cγ (PLCγ) (7).

The physiological relevance of TREM2 and DAP12 is demonstrated by loss-of-function mutations of either gene that cause polycystic lipomembranous osteodysplasia with sclerosteus leuoencephalopathy (PLOSL or Nasu-Hakola disease) associated with presenile dementia in the fourth decade of life in homozygous carriers (8, 9). Notably, rare variants of TREM2 in the heterozygous state have recently been identified by exome sequencing to increase the risk of late onset Alzheimer disease (LOAD) (10–14) and frontotemporal lobe dementia (15). Although the population frequency of the TREM2 R47H variant in the cohorts studied was much lower compared with the most common genetic risk factor, the apolipoprotein ε4 allele, the effects of both factors on the individual risk to develop LOAD were comparable (10, 11). TREM2 was also found to be up-regulated in microglia of amyloid precursor protein transgenic mouse models (10, 16, 17).
Processing of TREM2 by γ-Secretase

Here, we demonstrate that a C-terminal fragment of TREM2 generated by ectodomain shedding represents a novel substrate of the AD-associated γ-secretase. Interestingly, loss of γ-secretase activity leads to accumulation of TREM2 CTFs, impairing phosphorylation of the TREM2 adaptor protein DAP12. The combined data demonstrate a critical role of intramembranous proteolytic processing by γ-secretase in the signaling of TREM2 and thus, provide a functional link between both AD-associated factors.

EXPERIMENTAL PROCEDURES

Chemicals—Unless noted otherwise, all chemicals used for the described experiments were purchased in per analysi grade from Sigma-Aldrich, Roche Applied Science, Carl Roth (Karlsruhe, Germany), or AppliChem (Darmstadt, Germany). Primers for cloning were obtained from Fermentas (St. Leon-Rot, Germany). The radiochemicals were from Hartmann Analytic (Braunschweig, Germany). The following antibodies were used: anti-HA and anti-β-actin (Sigma-Aldrich), 9E10 against c-myc (Developmental Studies Hybridoma Bank, Iowa City, IA), anti-FLAG (Sigma-Aldrich), anti-GFP (Roche Applied Science), anti-mouse IgG and anti-rabbit IgG antibody conjugated with horseradish peroxidase (Sigma-Aldrich), anti-mouse IgG and anti-rabbit IgG antibody conjugated with Alexa Fluor 488 or Alexa Fluor 546 (Molecular Probes).

cDNA Constructs—For cloning of the different TREM2 and DAP12 constructs, specific primers containing HindIII, Xhol, or SfiI restriction sites were designed and used to amplify the corresponding DNA by PCR. For cloning of the phosphosite mutants of DAP12, internal primers were designed containing base exchanges generating base triplets for Phe at amino acid positions 92 and 103. The sequences of all primers are available upon request. Amplified DNA fragments were digested with HindIII, Xhol, or SfiI and ligated into pSecTag Hygro B vector using T4 ligase. Chemically competent Escherichia coli DH5α were transformed with plasmid DNAs and spread on LB agar supplemented with antibiotics. Single colonies were used to inoculate 2 ml of LB medium supplemented with antibiotics and grown overnight at 37 °C. After plasmid preparation, the sequence of the cloned DNA was checked by sequencing. The radiochemicals were from Hartmann Analytic (Braunschweig, Germany). The following antibodies were used: anti-HA and anti-β-actin (Sigma-Aldrich), 9E10 against c-myc (Developmental Studies Hybridoma Bank, Iowa City, IA), anti-FLAG (Sigma-Aldrich), anti-GFP (Roche Applied Science), anti-mouse IgG and anti-rabbit IgG antibody conjugated with horseradish peroxidase (Sigma-Aldrich), anti-mouse IgG and anti-rabbit IgG antibody conjugated with Alexa Fluor 488 or Alexa Fluor 546 (Molecular Probes).

Cell Culture and Transfection—Both HEK293 and COS7 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) Glutamax containing 4.5 g/liter D-glucose (Invitrogen) supplemented with 10% fetal calf serum (FCS; PAN-Biotec, Aidenbach, Germany) and 1% penicillin/streptomycin solution (50 units/ml penicillin, 50 μg/ml streptomycin; Invitrogen) at 37 °C, 95% humidity, and 5% CO2. Sodium deoxycholic acid was added to a final concentration of 0.02% and incubated for 15 min. TCA was then added to a final concentration of 10%, and the mixtures were incubated for 1 h on ice. Precipitated proteins were collected by centrifugation for 15 min at 16,000 rcf and 4 °C and washed twice with ice-cold acetone. The washed pellets were air-dried, resuspended in 35 μl of Tris-SDS buffer (50 mm Tris, 1% SDS in dH2O), and incubated for 10 min at 50 °C. Finally, SDS-sample buffer was added, and samples were subjected to separation by SDS-PAGE.

Biotinylation of Cell Surface Proteins—Cells were cultured on poly-l-lysine-coated dishes. After two washes with ice-cold PBS, cells were incubated with 2 ml of biotin solution (0.5 mg/ml sulfo-NHS-biotin (Thermo Scientific) in PBS) for 30 min on ice under constant gentle shaking. Cells were then washed three times with 20 ml glycine in PBS; the last washing solution was kept on cells for 15 min. Cells were then lysed in 900 μl of STEN lysis buffer for 15 min on ice. After centrifugation for 10 min at 16,000 rcf and 4 °C, 50 μl of streptavidin-agarose (Invitrogen) was added to the lysates, and the mixture
was incubated overnight at 4 °C on an overhead shaker. Finally, the streptavidin–agarose was washed four times for 10 min each with STEN buffer (50 mM Tris, 500 mM NaCl, 2 mM EDTA, 0.2% Nonidet P-40 in dH2O, pH 7.6), pelleted by centrifugation for 3 min at 600 rcf and 4 °C and resuspended in SDS-sample buffer and separated by SDS-PAGE.

**Radiolabeling with \(^{32}P\)j upon Activation of TREM2—**Cells were grown on poly-\(-\)lysine-coated dishes and starved in phosphate-free DMEM (Invitrogen) for 1 h. After incubation for 1 h in labeling medium (phosphate-free DMEM supplemented with 0.5 mM J3, 5°C, 5% CO\(_2\), TREM2 was activated by 10\(\mu\)g/ml anti-myc antibody. 200\(\mu\)M orthovanadate was used to stabilize the DAP12 phosphorylation. The cells were then incubated for another hour, washed once with PBS, and washed in 1 ml of STEN lysis buffer. DAP12 was then precipitated from the cleared lysates with anti-HA antibody coupled to protein G-Sepharose beads (Invitrogen). The beads were pelleted by centrifugation for 2 min at 9300 rcf and 4 °C before they were washed once with STEN-NaCl buffer (50 mM Tris, 500 mM NaCl, 2 mM EDTA, 0.2% Nonidet P-40 in dH2O, pH 7.6) and twice with STEN buffer. Finally, beads were resuspended in 20 \(\mu\)l of SDS-sample buffer.

**Analysis of PIP2—**Cos7 cells were plated on Ibidi \(\mu\)-dishes and were transfected with the PIP2 sensor, TREM2, and DAP12. Cells were then incubated for 24 h in presence or absence of 10\(\mu\)M DAPT. The fluorescence intensity of the PIP2 sensor was recorded every 10 min for 20 min in a time lapse setup. After adding c-myc antibody (10\(\mu\)g/ml) to activate TREM2, fluorescence intensity was further recorded every 10 min for 100 min. For quantification, the average fluorescence intensity before antibody application was set as \(F_0\), and \(\Delta F/F_0\) was calculated for every time point.

**Densitometric Quantification and Statistical Analysis—**Protein signals were quantified by densitometric analysis using Quantity One\textsuperscript{®} software (Bio-Rad). Statistical analyses were carried out by a two-sided Student’s \(t\) test (\(t\) test). For comparison of more than two individual groups, one-way analysis of variance with a Newman-Keuls ad hoc test was used. If not indicated otherwise, the diagrams show mean values ± corresponding S.E. of three independent experiments. Significance values are indicated by asterisks: *, \(p < 0.05\); **, \(p < 0.01\); ***, \(p < 0.001\).

**RESULTS**

**Proteolytic Shedding of the TREM2 Ectodomain—**TREM2 has been identified as a novel strong risk factor for LOAD, but it is unknown how TREM2 contributes to the disease (10, 11). To characterize the cellular metabolism of TREM2, we first analyzed whether this receptor undergoes proteolytic processing that might regulate its expression levels at the cell surface. Because the endogenous ligand of TREM2 is unknown and available antibodies do not reliably detect endogenously expressed TREM2, we first generated a TREM2 variant that carries a myc tag at the ectodomain, and an additional GFP-tag at the intracellular C terminus (myc-TREM2-GFP; Fig. 1A). To enable efficient transport of TREM2 to the cell surface, this TREM2 variant was co-expressed along with its adaptor molecule DAP12, which was tagged with a hemagglutinin epitope (DAP12-HA). As members of the matrix metalloprotease (MMP) family or the A Disintegrin And Metalloprotease (ADAM) family are major proteases involved in the cleavage of cell surface proteins, COS7 cells were incubated in absence or presence of batimastat, a well known inhibitor of proteases of both families (19, 20). In control cells, only low levels of cell surface-localized TREM2 were detected, although GFP detection indicated robust cellular expression (Fig. 1A). Interestingly, treatment with batimastat resulted in a ~3-fold increase of cell surface-localized TREM2 (313.4 ± 18.8% versus 100 ± 10.7%; Fig. 1A).

Western immunoblotting further confirmed the inhibition of TREM2 ectodomain shedding by batimastat, as the treatment increased the levels of full-length TREM2 (TREM2 FL) in the membrane fraction and decreased the amount of the secreted TREM2 ectodomain variants (TREM2 ECD: 14.6 ± 2.4% versus 100 ± 14.6%; Fig. 1B). Because TREM2 contains putative glycosylation sites in its ectodomain, the different bands for the full-length receptor in the membrane and the extracellular fragment in the culture supernatant might represent different glycosylation variants. We also detected a lower molecular mass species of TREM2 of about 48 kDa, likely representing a C-terminal fragment of TREM2 tagged with GFP (TREM2 CTF-GFP; Fig. 1B). Consistent with decreased ectodomain shedding, levels of the TREM2 CTF were decreased upon incubation with batimastat (17.2 ± 0.5% versus 100 ± 10.6%; Fig. 1B). These combined results indicate that TREM2 undergoes ectodomain shedding by a protease of the ADAM or MMP family.

**Intramembranous Cleavage of the TREM2 C-terminal Fragment by \(\gamma\)-Secretase—**Having established the ectodomain shedding of TREM2, we next tested whether the resulting membrane-tethered TREM2 CTF represents a substrate for \(\gamma\)-secretase, a major protease complex involved in intramembranous cleavage of type I membrane proteins after precedent removal of globular ectodomains. To enable the specific detection of proteolytic fragments, we transfected HEK293 cells with a Trem2 FL variant carrying a FLAG- and myc/His epitope at its N and C terminus, respectively (Fig. 2A). Western immunoblotting with anti-c-myc antibodies revealed the expression of ~35-kDa and ~17-kDa Trem2 variants, consistent with the expected molecular masses of full-length TREM2 and its membrane-bound CTF, respectively (without a GFP tag, compare with Fig. 1). Interestingly, the pharmacological inhibition of \(\gamma\)-secretase with DAPT led to a significant increase of TREM2 CTFS (239.6 ± 10.8% versus 100 ± 18.2%; Fig. 2A). To further confirm these findings, the effect of genetic \(\gamma\)-secretase inhibition on Trem2 CTF accumulation was investigated. HEK293 cells stably overexpressing wild type (WT) or a dominant negative (DN) variant of presenilin 1 (PS1) were co-transfected with cDNAs encoding Trem2 and DAP12 (Fig. 2B). Consistent with the pharmacological \(\gamma\)-secretase inhibition, the expression of the PS1 DN mutant also led to significant Trem2 CTF accumulation compared with PS1 WT-expressing cells (184.9 ± 0.5% versus 100 ± 6%).

It has been shown that \(\gamma\)-secretase selectively processes C-terminal stubs of proteins with short (10–15 amino acids) ectodomains (21, 22). Thus, we next generated a Trem2 vari-
ant lacking the TREM2 ectodomain (FLAG-TREM2/ECD-myc/His). Expression of this construct revealed a marked accumulation in HEK293 PS1 DN compared with HEK293 PS1 WT cells (258.8 ± 43.5% versus 100 ± 16.7%; Fig. 2C). To further prove processing of TREM2 by γ-secretase, we performed in vitro γ-secretase cleavage assays using the myc-TREM2-GFP construct (Fig. 2D). By Western immunoblotting we detected the TREM2 CTF fused to GFP (∼48 kDa) in the pellet fraction containing cellular membranes. Notably, in the supernatant fraction that should contain soluble products released from the membrane upon γ-secretase cleavage, we detected a TREM2 band of ∼35 kDa, fitting well with the putative size of the TREM2 ICD fused to GFP. This band was strongly decreased in presence of DAPT (Fig. 2D). Together, these data demonstrate that the C-terminal fragment of TREM2 generated by ectodomain shedding represents a substrate for γ-secretase.

Accumulation of TREM2 CTFs at the Cell Surface upon Inhibition of γ-Secretase—γ-Secretase cleaves its substrates mainly at the cell surface or intracellular endocytic compartments (23–25). To specifically test whether inhibition of γ-secretase results in accumulation of TREM2 CTF at the cell surface, we first carried out cell surface biotinylation experiments upon cell incubation in absence or presence of the γ-secretase inhibitor DAPT (Fig. 3A). The pulldown of biotinylated proteins and subsequent detection of TREM2 FL or its CTF demonstrated a strong accumulation of TREM2 CTF and a less pronounced increase of TREM2 FL at the cell surface upon γ-secretase inhibition (Fig. 3A). To further confirm the specific accumulation of TREM2 CTF at the cell surface, COS7 cells were co-transfected with FLAG-tagged TREM2ΔECD-myc/His and DAP12-HA and incubated in absence or presence of DAPT for 24 h. The specific immunocytochemical detection of the TREM2 CTF at the plasma membrane...
FIGURE 2. Cleavage of TREM2 C-terminal fragments by γ-secretase. A–C, native HEK293 cells (A) or HEK293 cells stably overexpressing PS1 WT or PS1 DN variants (B and C) were co-transfected with FLAG-DAP12-HA and FLAG-TREM2-myc/His (A and B) or with FLAG-TREM2ΔECD-myc/His (C) and cultured for 24 h. Membrane proteins were separated by SDS-PAGE, and TREM2 variants were detected by Western immunoblotting with anti-myc antibody. Bar charts show the quantification of TREM2 CTF/FL ratios (A and B; n = 3) or relative levels of TREM2 CTFs (C; n = 2). Statistical determination was done by a two-tailed t test (A) (n = 3) or one-way analysis of variance ANOVA (B) (n = 3). D, in vitro γ-secretase activity assay. Membranes of HEK293 cells expressing myc-TREM2-GFP were isolated and incubated for 2 h in the absence or presence of 10 μM DAPT. Reaction mixtures were separated by centrifugation into membrane (Membr.) and supernatant (Sup.) fractions. TREM2 CTF-GFP in the membrane fraction and soluble TREM2 ICD-GFP in the supernatant was detected by Western immunoblotting with anti-GFP antibodies. The soluble TREM2 ICD-GFP was strongly reduced after incubation with DAPT. Bar chart shows the quantification of TREM2 ICD/CTF ratios (n = 2). Error bars, S.E. **, p < 0.01; ***, p < 0.001.
via its extracellular FLAG epitope revealed a punctuated pattern in the control cells, typical for cell surface-localized proteins (Fig. 3B). Cell treatment with DAPT increased the surface levels of TREM2 CTFs (319.2 ± 40.8% versus 100 ± 10.32%). Together with the biochemical experiments (Fig. 3A), these data demonstrate a selective accumulation of TREM2 CTF at the cell surface upon γ-secretase inhibition.

Inhibition of γ-Secretase Impairs the Interaction of TREM2 with Its Signaling Adaptor Protein DAP12—TREM2 interacts with its co-receptor DAP12 via charged amino acid residues in their transmembrane domains (2). This electrostatic interaction is critical for the signaling of activated TREM2 to its adaptor protein DAP12. Thus, we next tested whether γ-secretase inhibition affects the interaction of TREM2 with DAP12. To allow specific detection of cell surface-localized complexes of TREM2 CTF and DAP12, we co-expressed the TREM2ΔECD variant with a FLAG tag in the ectodomain and the DAP12-HA-tagged variant (Fig. 4A). After DAPT treatment, living cells were incubated with anti-FLAG antibodies on ice, fixed, and permeabilized. DAP12 localization was visualized with a specific antibody against the HA tag. TREM2 CTF-positive structures were detected with anti-FLAG primary antibodies followed by Alexa Fluor 488-coupled secondary antibodies. Bar graph shows the quantification of TREM2 CTF-positive structures in five randomly chosen areas of 75 × 75 pixels in 10 cells each. Insets show enlarged images of boxed areas. Scale bars represent 20 μm. Statistical analyses were done by using a two-tailed t test. Error bars, S.E., *, p < 0.05; **, p < 0.001.

FIGURE 3. TREM2 CTFs accumulate at the cell surface after γ-secretase inhibition. A, HEK293 cells were transfected with FLAG-TREM2-myc/His in combination with FLAG-DAP12-HA and incubated for 24 h in absence or presence of 10 μM DAPT. Surface proteins were labeled with sulfo-NHS-biotin for 30 min. Cells were lysed and biotin-labeled proteins precipitated with streptavidin-coated agarose beads. Aliquots of cell lysates and streptavidin-precipitates were separated by SDS-PAGE, and TREM2 was detected by Western immunoblotting with anti-myc antibodies. Treatment with DAPT increases the cell surface expression of TREM2. Bar graphs show the quantification of TREM2 CTF/FL ratios (n = 3). B, COS7 cells were co-transfected with DAP12-HA and FLAG-TREM2ΔECD-myc/His and incubated for 24 h in presence or absence of 10 μM DAPT. TREM2 CTF was visualized at the cell surface of living cells by anti-FLAG primary and Alexa Fluor 488-coupled secondary antibodies. Bar graph shows the quantification of TREM2 CTF-positive structures in five randomly chosen areas of 75 × 75 pixels in 10 cells each. Insets show enlarged images of boxed areas. Scale bars represent 20 μm. Statistical analyses were done by using a two-tailed t test. Error bars, S.E., *, p < 0.05; **, p < 0.001.
out γ-secretase inhibition by in vivo radiolabeling with $^{32}$P. After cell lysis, DAP12 was immunoprecipitated and phosphate incorporation analyzed by autoradiography. In control cells, two weakly phosphorylated variants of DAP12 were detected (Fig. 4B). $^{32}$P radiolabeling strongly increased after the inhibition of tyrosine phosphatases by orthovanadate, indicating efficient phosphorylation and rapid dephosphorylation of DAP12 upon activation of TREM2 (Fig. 4B). A variant of DAP12 with mutated phosphorylation sites (DAP12 Y92F/Y103F) did not undergo phosphorylation, demonstrating the specific labeling of these tyrosine residues. Interestingly, the inhibition of γ-secretase led to a complete suppression of phosphate incorporation into the lower migrating variant of DAP12, even in the presence of orthovanadate (Fig. 4B), demonstrating impaired signaling of TREM2 to its adaptor protein DAP12.

Accumulation of the TREM2 C-terminal Fragment Impairs Phosphatidylinositol Metabolism—DAP12 has been previously linked to the activation of PLCγ, which hydrolyzes PIP$_2$ to inositol 1,4,5-trisphosphate and diacylglycerol (7, 26). Thus, impairment of DAP12 signaling by γ-secretase inhibition might decrease PLCγ activity thereby increasing PIP$_2$ levels in the cell. To test this hypothesis, we analyzed changes in PIP$_2$ levels in a time lapse experiment after activation of TREM2-DAP12 signaling by cross-linking TREM2 with anti-myc antibodies. To visualize PIP$_2$ in this experimental setup, we took advantage of a previously described PIP$_2$ sensor, consisting of the pleckstrin homology domain of PLCγ fused to GFP (27, 28). COS7 cells were co-transfected with this PIP$_2$ sensor, myc-TREM2-mCherry and DAP12-HA and incubated for 24 h in the presence or absence of DAPT. In response to TREM2-DAP12 activation by antibody cross-linking, the fluorescence intensity remained constant in DAPT-treated cells, with only a small decrease due to photobleaching (Fig. 5A, blue line). In contrast, the fluorescence intensity in cells incubated without DAPT steadily decreased after application of antibody (Fig. 5A, red line), indicating a reduction of PIP$_2$ levels. Cells expressing the PIP$_2$ sensor alone did not respond to antibody treatment (Fig. 5A, gray line), indicating specific signal transduction via TREM2. Together, these results indicate that the inhibition of γ-secretase interferes with TREM2-dependent regulation of PIP$_2$ levels at the plasma membrane.

DISCUSSION

Here, we show that TREM2 represents a novel substrate for γ-secretase and thereby unraveled a functional connection of two important factors involved in the pathogenesis of AD. The
The present data demonstrate that the inhibition of γ-secretase leads to a strong accumulation of the TREM2 CTF at the cell surface and trapping of its adaptor TYROBP/DAP12, which then impairs the signaling function of full-length TREM2. We also show that the full-length TREM2 undergoes ectodomain shedding before γ-secretase cleavage and thus represents a canonical substrate for regulated intramembrane proteolysis.

Although the responsible sheddase remains to be determined, the efficient inhibition of ectodomain shedding by batimastat suggests the involvement of metalloproteases of the MMP and/or ADAM family. Both classes of proteases are highly specific for further intramembrane cleavage by γ-secretase. Thus, the initial cleavage of TREM2 by a shedding enzyme results in the liberation of a globular ectodomain which is a prerequisite for further intramembrane cleavage by γ-secretase. Although the responsible sheddase remains to be determined, the efficient inhibition of ectodomain shedding by batimastat suggests the involvement of metalloproteases of the MMP and/or ADAM family.
expressed in microglia cells (36) and can cleave several important receptors and cytokines (37).

Soluble variants of TREM2 and its homolog TREM1 have been detected in human cerebrospinal fluid (CSF) (38) or in blood of septic shock patients (39, 40). Although our data clearly support a release of soluble TREM2 by proteolytic shedding, additional mechanisms have also been proposed, including alternative splicing of the TREM2 mRNA that could lead to shortened variants without the transmembrane domains (41). However, as metalloprotease inhibitors also decreased the levels of soluble TREM1 variants (39, 42), proteolytic shedding appears to be a general mechanism for the release of both TREM receptors. After shedding of the ectodomain, the remaining TREM2 CTF is further degraded by γ-secretase (Fig. 5B). Interestingly, presenilin has been previously shown to be involved in microglial phagocytosis and migration, but the molecular mechanisms remain to be identified (43, 44). Thus, it will be important to investigate further whether these observed effects also involve misprocessing of TREM2.

Our data demonstrate that decreased processing of TREM2 CTFs by γ-secretase indeed interferes with TREM2-dependent signaling. The findings also indicate that the accumulation of TREM2 CTFs traps the adaptor DAP12 at the cell membrane, thereby decreasing its availability to interact with functional full-length TREM2 (see Fig. 5B). It is important to note that the TREM2 CTF generated by ectodomain shedding still contains the motif for the electrostatic interaction with DAP12. Interestingly, the phosphorylation of DAP12 upon activation of the full-length receptor was strongly decreased in cells with accumulated TREM2 CTF upon γ-secretase inhibition. Moreover, upon stimulation of TREM2, PI(3)K metabolism was impaired by inhibition of γ-secretase. Alterations in phosphoinositide levels have been previously observed in cell lines expressing presenilin-1 FAD-associated mutations, but the molecular mechanisms were not identified (45, 46). Because DAP12 can negatively regulate phosphoinositid 3-kinase (PI3K) (47–49) and activate PLCγ (7, 26), our data suggest that impaired activation of DAP12 upon inhibition of γ-secretase could either result in decreased suppression of PI3K or decreased activity of the PLCγ and thus, elevation of PI(2) levels at the plasma membrane.

It is interesting to note that the recently identified rare variants of TREM2, which significantly increase the risk of AD, might result in a loss of function, either by introduction of a stop codon (p.Q33X variant) or by affecting ligand binding (p.R47H variant) (10, 11). Thus, these mutations might also impair signaling to DAP12.

Together, the data from our study demonstrate that TREM2, a novel risk factor for LOAD, and the presenilins, the most common factor for familial early onset AD, are both involved in the same signaling pathway. Thus, it will be interesting to further investigate the role of TREM2 and γ-secretase in microglia and neuroinflammatory processes associated with AD and frontotemporal lobe dementia.

REFERENCES

1. Colonna, M. (2003) TREMs in the immune system and beyond. Nat. Rev. Immunol. 3, 445–453
2. Bouchon, A., Dietrich, J., and Colonna, M. (2000) Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J. Immunol. 164, 4991–4995
3. Bouchon, A., Hernández-Munain, C., Cella, M., and Colonna, M. (2001) A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J. Exp. Med. 194, 1111–1122
4. Sessa, G., Podini, P., Mariani, M., Meroni, A., Sprefico, R., Sinigaglia, F., Colonna, M., Panina, P., and Meldolesi, J. (2004) Distribution and signaling of TREM2/DAP12, the receptor system mutated in the human PLOS dementia. Eur. J. Neurosci. 20, 2617–2628
5. Prada, I., Ongania, G. N., Buonsanti, C., Panina-Bordignon, P., and Meldolesi, J. (2006) Triggering receptor expressed in myeloid cells 2 (TREM2) trafficking in microglial cells: continuous shuttling to and from the plasma membrane regulated by cell stimulation. Neuroscience 140, 1139–1148
6. Lanier, L. L., Corlliss, B. C., Wu, J., Leong, C., and Phillips, J. H. (1998) Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 391, 703–707
7. Lowell, C. A. (2011) Src family and Syk kinases in activating and inhibitory pathways in innate immune cells: signaling cross-talk. Cold Spring Harb. Perspect. Biol. 3, a002352
8. Paloneva, J., Kestiälä, M., Wu, J., Salminen, A., Böhling, T., Ruotsalainen, V., Hakola, P., Bakker, A. B., Phillips, J. H., Pekkarinen, P., Lanier, L. L., Timonen, T., and Peltonen, L. (2000) Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat. Genet. 25, 357–361
9. Paloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., Bianchin, M., Bird, T., Miranda, R., Salmaggi, A., Tranebjaerg, L., Konttinen, Y., and Peltonen, L. (2002) Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am. J. Hum. Genet. 71, 656–662
10. Guerreiro, R., Wojtas, A., Bras, I., Carraquillo, M., Roqeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S., Youkun, S., Hrazati, L., Collinge, J., Pocock, J., Lashley, T., Williams, J., Lambert, J. C., Amoury, P., Goate, A., Rademakers, R., Morgan, K., Powell, J., St George-Hyslop, P., Singleton, A., and Hardy, J., and Alzheimer Genetic Analysis Group (2013) TREM2 variants in Alzheimer’s disease. N. Engl. J. Med. 368, 117–127
11. Jonsson, T., Stensfjord, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Neadal, J., Bjornsson, H., Cutten, J., Loh, A. L., Lah, J. J., Rujescu, D., Hample, H., Giegling, I., Andreasen, O. A., Engedal, K., Ulstein, I., Djurovic, S., Ibrahim-Verbaas, C., Hofman, A., Ikram, M. A., van Duijn, C. M., Thorsteinsson, A., Kong, A., and Stefansson, K. (2013) Variant of TREM2 associated with the risk of Alzheimer’s disease. N. Engl. J. Med. 368, 107–116
12. Benitez, B. A., Cooper, B., Pastor, P., Jin, S. C., Lorenzo, E., Cervantes, S., and Cruchaga, C. (2013) TREM2 is associated with the risk of Alzheimer’s disease in Spanish population. Neurobiol. Aging 34, 1711
13. Jiang, T., Yu, J. T., Zhu, X. C., and Tan, L. (2013) TREM2 in Alzheimer’s disease. Mol. Neurobiol. 48, 180–185
14. Pottier, C., Wallon, D., Rousseau, S., Rovelet-Lecrux, A., Richard, A. C., Rollin-Sillaire, A., Frebourg, T., Campion, D., and Hannequin, D. (2013) TREM2 R47H variant as a risk factor for early-onset Alzheimer’s disease. J. Alzheimer’s Dis. 35, 45–49
15. Guerreiro, R. J., Lohmann, E., Bras, J. M., Gibbs, J. R., Rohrer, J. D., Gurunlian, N., Dursun, B., Bögic, B., Hanagasi, H., Gurvit, H., Emre, M., Singleton, A., and Hardy, J. (2013) Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome with out bone involvement. JAMA Neurol. 70, 78–84
16. Frank, S., Burbach, G. J. B., Bonin, M., Walter, M., Streit, W., Bechmann, I., and Deller, T. (2008) TREM2 is up-regulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 56, 1438–1447
17. Melchior, B., Garcia, A. E., Hsiung, B. K., Lo, K. M., Doose, J. M., Cameron Thrash, J. C., Stalder, A. K., Stalder, M., Neumann, H., and Carson, M. J. (2010) Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer’s disease. ASN Neuro. 2, e00037
18. Tamboli, I. Y., Hample, H., Tien, N. T., Tolksdorf, K., Breiden, B.,
Processing of TREM2 by γ-Secretase

Mathews, P. M., Saftig, P., Sandhoff, K., and Walter, J. (2011) Sphingolipid storage affects autophagic metabolism of the amyloid precursor protein and promotes Aβ generation. *J. Neurosci.* 31, 1837–1849

19. Hernandez-Pando, R., Orozco, H., Arriaga, K., Pavón, L., and Rook, G. (2000) Treatment with BB-94, a broad spectrum inhibitor of zinc-dependent metalloproteinas, causes deviation of the cytokine profile towards type-2 in experimental pulmonary tuberculosis in Balb/c mice. *Int. J. Exp. Pathol.* 81, 199–209

20. Sahin, U., Weskamp, G., Kelly, K., Zhou, H. M., Higashiyama, S., Peschon, J., Hartmann, D., Saftig, P., and Blobel, C. P. (2004) Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. *J. Cell Biol.* 164, 769–779

21. Hemming, M. L., Elias, J. E., Gygi, S. P., and Selkoe, D. J. (2008) Proteomic profiling of γ-secretase substrates and mapping of substrate requirements. *PLoS Biol.* 6, e257

22. Struhl, G., and Adachi, A. (2000) Requirements for presenilin-dependent cleavage of Notch and other transmembrane proteins. *Mol. Cell* 6, 625–626

23. Walter, J., Kaether, C., Steinér, H., and Haass, C. (2001) The cell biology of Alzheimer’s disease: uncovering the secrets of secretases. *Curr. Opin. Neurol.* 14, 585–590

24. Peraus, G. C., Masters, C. L., and Beyreuther, K. (1997) Later compartmentalization of presenilin-1. *J. Neurosci.* 17, 7714–7724

25. Kaether, C., Lammich, S., Edbauer, D., Ertl, M., Rietdorf, J., Capell, A., Steiner, H., and Haass, C. (2002) Presenilin-1 affects trafficking and processing of BAPP and is targeted in a complex with nicastrin to the plasma membrane. *J. Cell Biol.* 158, 551–561

26. Mao, D., Eppler, H., Utzgenannt, B., Novack, D. V., and Facci, R. (2006) PLCγ2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. *J. Clin. Invest.* 116, 2869–2879

27. Stauffer, T. P., Ahn, S., and Meyer, T. (1998) Receptor-induced transient reduction in plasma membrane PtdIns(4,5)P2 concentration monitored in living cells. *Curr. Biol.* 8, 343–346

28. Várnai, P., and Balla, T. (1998) Visualization of phosphoinositides that bind pleckstrin homology domains: calcium- and agonist-induced dynamic changes and relationship to myo-[3H]inositol-labeled phosphoinositide pools. *J. Cell Biol.* 143, 501–510

29. De Strooper, B., and Annaert, W. (2010) Novel research horizons for presenilin-1. *Nat. Rev. Mol. Cell Biol.* 11, 235–260

30. Selkoe, D. J., and Wolfe, M. S. (2007) Presenilin: running with scissors in microglia compared to leukocytes and they link microglia activation with cytokine levels. *Glia* 55, 516–526

31. Reiss, K., and Saftig, P. (2009) The “A Disintegrin And Metalloprotease” (ADAM) family of sheddases: physiological and cellular functions. *Semin. Cell Dev. Biol.* 20, 126–137

32. Steiner, H., and Haass, C. (2000) Intramembrane proteolysis by presenilin-1. *Nat. Rev. Mol. Cell Biol.* 1, 343–350

33. Walter, J., Kaether, C., Steinér, H., and Haass, C. (2001) The cell biology of Alzheimer’s disease: uncovering the secrets of secretases. *Curr. Opin. Neurol.* 14, 585–590

34. Peraus, G. C., Masters, C. L., and Beyreuther, K. (1997) Later compartmentalization of presenilin-1. *J. Neurosci.* 17, 7714–7724

35. Kaether, C., Lammich, S., Edbauer, D., Ertl, M., Rietdorf, J., Capell, A., Steiner, H., and Haass, C. (2002) Presenilin-1 affects trafficking and processing of BAPP and is targeted in a complex with nicastrin to the plasma membrane. *J. Cell Biol.* 158, 551–561

36. Mao, D., Eppler, H., Utzgenannt, B., Novack, D. V., and Facci, R. (2006) PLCγ2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. *J. Clin. Invest.* 116, 2869–2879

37. Reiss, K., and Saftig, P. (2009) The “A Disintegrin And Metalloprotease” (ADAM) family of sheddases: physiological and cellular functions. *Semin. Cell Dev. Biol.* 20, 126–137

38. Piccio, L., Buonsanti, C., Celli, M., Tassi, I., Schmidt, R. E., Fenoglio, C., Rinker, J., 2nd, Naismith, R. T., Panina-Bordignon, P., Passini, N., Galimberti, D., Scarolini, E., Colonna, M., and Cross, A. H. (2008) Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. *Brain* 131, 3081–3091

39. Gibot, S., Kolopp-Sarda, M. N., Bené, M. C., Bollaert, P. E., Lozinskiwsky, A., Mory, F., Levy, B., and Faure, G. C. (2004) A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. *J. Exp. Med.* 200, 1419–1426

40. Mahdy, A. M., Lowes, D. A., Galley, H. F., Bruce, J. E., and Webster, N. R. (2006) Production of soluble triggering receptor expressed on myeloid cells by lipopolysaccharide-stimulated human neutrophils involves de novo protein synthesis. *Clin. Vaccine Immunol.* 13, 492–495

41. Gingras, M. C., Lapillonne, H., and Margolin, J. F. (2002) TREM-2, MDL-1, and DAP12 expression is associated with a mature stage of myeloid development. *Mol. Biol. Cell.* 13, 817–824

42. Gómez-Piña, V., Soares-Schanoski, A., Rodríguez-Rojas, A., Del Fresno, C., García, F., Vallejo-Cremades, M. T., Fernández-Ruíz, I., Arnalich, F., Fuentes-Prior, P., and López-Collazo, E. (2007) Metalloproteinases shed TREM-1 ectodomain from lipopolysaccharide-stimulated human monocytes. *J. Immunol.* 179, 4065–4073

43. Farfara, D., Trudler, D., Segev-Amzaleg, N., Galron, R., Stein, R., and Frenkel, D. (2011) γ-Secretase component presenilin is important for microglia β-amyloid clearance. *Ann. Neurol.* 69, 170–180

44. Lee, J., Chan, S. L., and Mattson, M. P. (2002) Adverse effect of a presenilin-1 mutation in microglia results in enhanced nitric oxide and inflammatory cytokine responses to immune challenge in the brain. *Neurovascular Med.* 2, 29–45

45. Landman, N., Jeong, S. Y., Shin, S. Y., Voronen, S. V., Serban, G., Kang, M. S., Park, M. K., Di Paolo, G., Chung, S., and Kim, T. W. (2006) Presenilin mutations linked to familial Alzheimer’s disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism. *Proc. Natl. Acad. Sci. U.S.A.* 103, 19524–19529

46. Di Paolo, G., and Kim, T. W. (2011) Linking lipids to Alzheimer’s disease: cholesterol and beyond. *Nat. Rev. Neurosci.* 12, 284–296

47. Jiang, K., Zhong, B., Gihvary, D. L., Corliss, B. C., Vivier, E., Hong-Geller, E., Wei, S., and Djeu, J. Y. (2002) Syk regulation of phosphoinositide 3-kinase-dependent NK cell function. *J. Immunol.* 168, 3155–3164

48. Peng, Q., Malhotra, S., Torchio, J. A., Kerr, W. G., Coggeshall, K. M., and Humphrey, M. B. (2010) TREM-2 and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1. *Sci. Signal.* 3, ra38

49. Zompi, S., Hamerman, J. A., Ogasawara, K., Schweighoffer, E., Tybulewicz, V. L., Di Santo, J. P., Lanier, L. L., and Colucci, F. (2003) NKG2D triggers cytotoxicity in mouse NK cells lacking DAP12 or Syk family kinases. *Nat. Immunol.* 4, 565–572
Sequential Proteolytic Processing of the Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) Protein by Ectodomain Shedding and $\gamma$-Secretase-dependent Intramembranous Cleavage

Patrick Wunderlich, Konstantin Glebov, Nadja Kemmerling, Nguyen T. Tien, Harald Neumann and Jochen Walter

J. Biol. Chem. 2013, 288:33027-33036. doi: 10.1074/jbc.M113.517540 originally published online September 27, 2013

Access the most updated version of this article at doi: 10.1074/jbc.M113.517540

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 49 references, 14 of which can be accessed free at http://www.jbc.org/content/288/46/33027.full.html#ref-list-1